Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.30 |
| ▸ | KDM5A | P29375 | 2/20 | 0.30 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.30 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
| ▸ | GRK2 | P25098 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL539421 | 0.87 | — | — | |
| SCHEMBL9537234 | 0.83 | SIGMAR1 (0.54) | SIGMAR1CHRNB2CHRNA4CYP11B1CYP11B2 | |
| SCHEMBL1950016 | 0.71 | SIGMAR1 (0.43) | SIGMAR1CHRNB2CHRNA4 | |
| 5,6,7,8-Tetrahydroisoquinoline SCHEMBL28211 | 0.70 | SIGMAR1 (1.00) | SIGMAR1CHRNB2CHRNA4CYP11B1CYP11B2 | |
| SCHEMBL2388666 | 0.70 | — | — | |
| SCHEMBL29518090 | 0.70 | — | — | |
| SCHEMBL16031737 | 0.70 | — | — | |
| SCHEMBL4077470 | 0.69 | SIGMAR1 (0.95) | SIGMAR1CHRNB2CHRNA4CYP11B1CYP11B2 | |
| SCHEMBL20682524 | 0.69 | SIGMAR1 (0.95) | SIGMAR1CHRNB2CHRNA4CYP11B1CYP11B2 | |
| SCHEMBL19840372 | 0.69 | SIGMAR1 (0.95) | SIGMAR1CHRNB2CHRNA4CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0771196-B1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1999-12-08 | — | — | EP | claimed |
| US-5717109-A | CARBOXYCYCLOPROPYL GLYCINE DERIVATIVES; USEFUL FOR TREATMENT OF ACUTE OR CHRONIC NEURODEGENERATIVE CONDITIONS, AND AS ANTIPSYCHOTIC, ANTICONVULSANT, ANALGESIC, ANXIOLYTIC, ANTIDEPRESSANT AND ANTI-EMETIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-02-10 | — | — | US | claimed |
| EP-4028401-B1 | 4,4A,5,7,8,8A-HEXAPYRIDO[4,3-B][1,4]OXAZIN-3-ONE COMPOUNDS AS MAGL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2023-11-22 | — | — | EP | disclosed |
| EP-4028401-A1 | 4,4A,5,7,8,8A-HEXAPYRIDO[4,3-B][1,4]OXAZIN-3-ONE COMPOUNDS AS MAGL INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2022-07-20 | — | — | EP | disclosed |
| CN-114364682-A | Compound 4,4A,5,7,8, 8A-hexapyrido [4,3-B ] [1,4] oxazin-3-one as MAGL inhibitor | 豪夫迈·罗氏有限公司 | 2022-04-15 | — | — | CN | disclosed |
| US-20210094971-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2021-04-01 | — | — | US | disclosed |
| WO-2021048036-A1 | 4,4A,5,7,8,8A-HEXAPYRIDO[4,3-B][1,4]OXAZIN-3-ONE COMPOUNDS AS MAGL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-03-18 | — | — | WO | disclosed |
| EP-2970215-B1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND (DE) | 2019-04-17 | — | — | EP | disclosed |
| US-9650334-B2 | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2017-05-16 | — | — | US | disclosed |
| EP-2970215-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-20 | — | — | EP | disclosed |
| US-20140275086-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | US | disclosed |
| EP-0771196-A4 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1997-09-03 | — | — | EP | disclosed |
| EP-0774455-A1 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 1997-05-21 | — | — | EP | disclosed |
| EP-0774461-A1 | Excitatory amino acid derivatives | ELI LILLY AND COMPANY (US) | 1997-05-21 | — | — | EP | disclosed |
| EP-0774454-A1 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 1997-05-21 | — | — | EP | disclosed |
| EP-0771196-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-05-07 | — | — | EP | disclosed |
| WO-1996007405-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-03-14 | — | — | WO | disclosed |
| EP-0314852-B1 | Process for the preparation of 1-substituted imidazole-carbonic acid and derivatives | CIBA GEIGY AG (CH) | 1993-11-18 | — | — | EP | disclosed |
| US-4921955-A | Process for the synthesis of 1-substituted imidazole-5-carboxylic acids and carboxylic acid derivatives | CIBA-GEIGY CORPORATION (US) | 1990-05-01 | — | — | US | disclosed |
| EP-0314852-A2 | Process for the preparation of 1-substituted imidazole-carbonic acid and derivatives | CIBA-GEIGY AG (CH) | 1989-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275086-A1 | PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | SLC6A7, GFPT1, SUGT1 | SIGMAR1 1739/4885CHRNB2 4647/4885CHRNA4 4587/4885 |
| US-20210094971-A1 | HETEROCYCLIC COMPOUNDS | CYP1B1, CYP4B1, CYP4X1 | SIGMAR1 1402/4885CHRNB2 2684/4885CHRNA4 2737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.